Sulfamethoxazole/Trimethoprim Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber, few things are more frustrating than a patient calling back to report they can't fill their prescription. Sulfamethoxazole/trimethoprim (TMP-SMX, Bactrim, Septra) is one of the most prescribed antibiotics in the U.S., and while no active FDA shortage exists as of 2026, availability gaps — particularly for the oral suspension — continue to affect patients. This guide gives you what you need to proactively manage this with your patient panel.

Current TMP-SMX Availability Status (2026)

There is no active FDA-declared shortage of sulfamethoxazole/trimethoprim oral tablets (SS or DS) as of 2026. The drug is manufactured by multiple generic companies including Aurobindo, Actavis/TEVA, Amneal, Sun Pharma, and others. The IV formulation has historically seen intermittent shortages and providers should verify hospital formulary availability for inpatient use. The oral suspension (Sulfatrim, SMZ-TMP suspension) continues to experience localized availability challenges.

Clinical Indications Most Affected by Stock Gaps

Pediatric otitis media / UTIs: Oral suspension demand spikes seasonally; plan alternative prescriptions in advance.

PCP prophylaxis in HIV/immunocompromised patients: Long-term patients need reliable access; consider 90-day mail-order fills and have a backup plan (dapsone, atovaquone) documented in the chart.

Community-acquired MRSA skin infections: Tablets are generally available; stock gaps are rare but should be addressed promptly given the infection type.

Inpatient PCP treatment: IV TMP-SMX 15–20 mg/kg/day has had the most notable shortage history. Inpatient pharmacists should be consulted for alternatives if IV TMP-SMX is unavailable.

Therapeutic Substitution Guidance by Indication

Uncomplicated UTI:

Nitrofurantoin monohydrate/macrocrystals (Macrobid) 100 mg BID x 5–7 days — preferred first-line alternative per IDSA guidelines

Fosfomycin 3 g orally x 1 dose — convenient, good E. coli and Enterococcus coverage, but lower efficacy than TMP-SMX

Fluoroquinolones (ciprofloxacin 250 mg BID x 3 days) — reserve for complicated cases or culture-guided use; FDA safety warnings apply

MRSA Skin and Soft Tissue Infections (outpatient):

Doxycycline 100 mg BID x 5–14 days (avoid in pregnancy and children <8 years)

Clindamycin 300–450 mg TID — check local D-zone resistance before prescribing

PCP Prophylaxis (if TMP-SMX not tolerated or unavailable):

Dapsone 100 mg PO daily (check G6PD before initiating; contraindicated with G6PD deficiency)

Atovaquone 1500 mg PO daily with food — less effective than TMP-SMX; high cost

Aerosolized pentamidine 300 mg monthly via Respirgard II nebulizer — least effective; suitable only when oral agents not tolerated

Important Drug Interactions to Assess Before Prescribing TMP-SMX

Before prescribing, review for the following high-priority interactions:

Warfarin: TMP-SMX significantly potentiates warfarin's anticoagulant effect. Monitor INR closely; anticipate dose reduction.

Methotrexate: TMP-SMX reduces methotrexate renal clearance by ~40%, increasing toxicity risk. Avoid combination or monitor closely.

ACE inhibitors / ARBs / potassium-sparing diuretics: Risk of clinically significant hyperkalemia, especially in elderly patients and those with renal impairment. Monitor potassium.

Dofetilide: Contraindicated. TMP-SMX inhibits renal elimination of dofetilide, increasing QTc prolongation and risk of Torsades de Pointes.

Leucovorin (folinic acid) in PCP treatment: Contraindicated — associated with increased treatment failure and mortality in PCP.

How to Help Your Patients Find TMP-SMX in Stock

When patients can't find their prescription, the most practical tool you can recommend is medfinder. It calls pharmacies near the patient and texts them which ones have the medication in stock — eliminating the phone tag and wasted trips. See our detailed guide: how to help your patients find TMP-SMX in stock.

Resources for Monitoring Shortage Status

FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages

ASHP Drug Shortage Database: ashp.org/drug-shortages (includes clinical impact assessments)

Your pharmacy partner: Clinical pharmacists at your affiliated health system or PBM can provide real-time formulary and distributor availability data.